Home › Compare › KMGIF vs ABBV
KMGIF yields 6.95% · ABBV yields 3.06%● Live data
📍 KMGIF pulled ahead of the other in Year 1
Combined, KMGIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KMGIF + ABBV for your $10,000?
Kamigumi Co., Ltd. provides an integrated logistics services in Japan and internationally. The company offers harbor transportation services; warehousing storage and distribution processing services; and truck, air, and rail transportation services, as well as sea freight services. It also provides on-site factory services, including loading and unloading of ship-borne raw materials; transportation of materials to sites; and provision of secondary processing, product controls/shipping work, and environmental response work services. In addition, the company offers heavy cargo transportation services for transformer plants, industrial equipment, petrochemical plant equipment, and railcars. Further, it provides construction services for housing, warehouses, offices, and stores; offers breakdown and disposal services for large equipment and facilities, such as steel plant rolling mill production lines and large conveyor systems for sand and rock; designs and constructs steel structures; constructs and maintains amusement facilities; and provides machinery maintenance services. Additionally, the company engages in apartment rental; alcoholic beverage production; and restaurant businesses, as well as solar business. It also develops and leases commercial facilities, operates parking areas, and cultivates tomatoes. Kamigumi Co., Ltd. was founded in 1867 and is headquartered in Kobe, Japan.
Full KMGIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.